Cryptorchidism (Undescended Testes)
Prevalence, Fertility & Cancer Implications, and the Timing of Orchidopexy
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not applicable (condition; orchidopexy is standard surgical care)
Reference only. Not medical advice.
What can go wrong
Untreated or late-treated cryptorchidism risks impaired fertility (especially bilateral) and an elevated relative risk of testicular germ-cell cancer that orchidopexy reduces but does not eliminate. Orchidopexy is a surgical procedure with the usual operative risks (anesthesia, bleeding, infection, and a small rate of testicular atrophy or re-ascent). Hormonal therapy to induce descent is not recommended by major guidelines due to limited efficacy. Lifelong testicular self-examination is advised regardless of correction.
This is something to take to a clinician. The Atlas can tell you what is known about cryptorchidism (undescended testes) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Cryptorchidism, failure of one or both testes to descend into the scrotum, is the most common genital anomaly in male newborns, affecting roughly 2-5% of term boys at birth and a higher fraction of preterm boys. Many descend spontaneously in the first months, leaving about 1-1.5% persistent by 3-6 months. Testicular descent is a two-phase process (transabdominal, then inguinoscrotal) governed by INSL3 (Leydig-cell hormone, via the RXFP2 receptor) and androgen-dependent gubernacular migration. Persistent cryptorchidism is linked to impaired fertility and an increased relative risk of testicular germ-cell cancer; both risks are part of the broader testicular dysgenesis syndrome hypothesis. Guidelines (e.g. AUA 2014; Nordic consensus) recommend surgical orchidopexy by 6-18 months for testes that have not descended, to optimize outcomes.
The most common male genital birth anomaly, and a window that closes.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Descent has two phases: a transabdominal phase, where INSL3 from fetal Leydig cells (via RXFP2) thickens and anchors the gubernaculum, and an inguinoscrotal phase, which is androgen-dependent and brings the testis through the inguinal canal into the scrotum. Disruption of androgen action or INSL3 (genetic, or via fetal anti-androgen exposure during the masculinization window) impairs descent. The scrotum's cooler temperature is required for normal spermatogenesis; an intra-abdominal or inguinal testis sits warmer, progressively damaging germ cells, which is why timing of correction matters.
Why timing matters and what surgery does (and does not) fix
Histological studies show progressive loss of germ cells and failure of the normal gonocyte-to-spermatogonia transition in undescended testes over the first 1-2 years, motivating early orchidopexy. Orchidopexy improves fertility prospects (especially in bilateral cases) and brings the testis to a palpable position so future tumors can be detected, but it does NOT fully normalize cancer risk, the elevated risk reflects an intrinsic developmental abnormality of the gonad, not merely its location. Men with a history of cryptorchidism should be taught testicular self-examination.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Examination/position confirmation
- Fertility counseling (especially bilateral cases)
- Lifelong testicular self-exam / tumor awareness
What people get wrong
Often saidAn undescended testis will probably come down on its own at any age
ActuallyMost spontaneous descent occurs by 3-6 months; after that it is unlikely, and waiting past ~18 months worsens fertility and complicates cancer surveillance.
Often saidOrchidopexy eliminates the cancer risk
ActuallyIt lowers and enables monitoring of risk but does not abolish it, because the gonad itself is developmentally abnormal.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- How much of the cancer risk is intrinsic dysgenesis vs position/temperature?
- Do environmental anti-androgens during the fetal window drive the apparent rise in genital anomalies?
At a glance
- Prevalence at birth (term)
- ~2-5%
- Persistent by 6 months
- ~1-1.5%
- Descent hormones
- INSL3/RXFP2 and androgen
- Cancer risk
- Increased relative risk of testicular germ-cell tumor
- Orchidopexy timing
- By 6-18 months (guideline)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Cryptorchidism (Undescended Testes). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Nordic consensus on treatment of undescended testes2007
Recommended surgery between 6 and 12 months for best fertility/cancer outcomes
Pettersson et al., NEJM, age at orchidopexy and testis cancer2007
Surgery before puberty was associated with lower testicular-cancer risk than later surgery
AUA Guideline on cryptorchidism2014
Standardized evaluation, timing and against routine hormonal therapy for descent